Sandoz enters agreement for proposed trastuzumab biosimilar to treat selected HER2-positive cancer tumors

Image: Sandoz is set to commercialize proposed trastuzumab biosimilar. Photo: courtesy of dream designs / FreeDigitalPhotos.net.